Influenza Vaccine Equipment Market To Touch Valuation Of USD 51.53 Billion By 2032, At 18.21% CAGR: Astute Analytica

(MENAFN- GlobeNewsWire - Nasdaq) The global influenza vaccine equipment market surges with innovation and capacity expansion, driven by the persistent influenza burden and rising government support. technology shifts towards cell-based production and single-use systems, optimizing speed and flexibility. Asia Pacific ascends as a growth engine, while challenges lie in adapting to viral changes and managing costs.

New Delhi, April 04, 2024 (GLOBE NEWSWIRE) -- [203+ Pages] According to Astute Analytica, the global influenza vaccine equipment market is projected to reach US$ 51.53 billion by 2032, up from US$ 11.43 billion in 2023, at a CAGR of 18.21% during the forecast period 2024–2032.

Request Free Sample Copy @

The influenza vaccine equipment market finds its primary driving force in the persistent burden of influenza outbreaks worldwide. The World Health Organization (WHO) estimates that each year, annual flu epidemics cause 3-5 million severe illnesses, and between 290,000 and 650,000 respiratory deaths. In developed countries such as the US, the Centers for Disease Control and Prevention (CDC) said there were an estimated 38 million illnesses, 400,000 hospitalizations and 22,000 deaths due to the flu during the 2019-2020 season alone. However, staggering this maybe it's a constant reminder that we are in need of a robust market for vaccines. Global production for these vaccines has increased dramatically over time with numbers going from 1.5 billion doses in 2006 to 6.4 billion in 2019 according to WHO reports.

The COVID-19 pandemic played a big role within this market as well. When supply chains were disrupted manufacturer's concerns about COVID-19 and influenza co-infections led manufacturers to focus on influenza vaccination again. There was also an unprecedented amount of investment into vaccine technology and capacity building that benefited the influenza vaccine equipment market. Manufacturers are committed to scaling up their operations when it comes to producing more of these vaccines every day however speed isn't everything.

Companies like Seqirus invest heavily in new facilities and they're expanding their existing plants as well because innovation is still a priority in order to keep up with demand. While traditional egg-based production is still very much alive in this industry cell-based and recombinant DNA technologies have sparked a change within it thanks to their efficiency which further fuels demand for specialized vaccine production equipment.

Key Findings in Global Influenza Vaccine Equipment Market

Market Forecast (2032)	US$51.53 Billion
CAGR	18.21%
Largest Region (2023)	North America (37.23%)
By Type	Bioreactor (22.63%)
By End Users	Pharmaceutical & Biotechnology (53.36%)
Top Trends	Shift towards cell-based and recombinant influenza vaccine production technologies Increasing adoption of single-use bioreactors and other disposable equipment Growing importance of advanced process analytics and data-driven manufacturing
Top Drivers	High global incidence of influenza and its associated health burden Expanding global vaccine production capacity to meet rising demand Government initiatives and funding to support influenza vaccination programs
Top Challenges	The need to rapidly adapt production processes in response to changing influenza strains Rising costs of vaccine production and equipment procurement Ensuring regulatory compliance and stringent quality standards in vaccine manufacturing

Pharmaceutical Companies are the Key Buyers in Influenza Vaccine Equipment Market, Control Over 56% Market Revenue

Companies operating in the pharmaceutical and biotechnology sectors are the largest consumers within the influenza vaccine equipment market, holding an estimated share of 53.36%. The extensive demand for these companies is driven by several factors. The first factor that propels their relentless demand is ongoing research and development (R&D) efforts. In 2022 alone, the top 15 biopharma companies invested a combined $135 billion in R&D, with vaccines being a core component for many. Moreover, given the highly regulated nature of vaccine development, these companies must meet strict quality and safety standards that require sophisticated equipment.

To produce influenza vaccines at a global scale, pharmaceutical and biotech manufacturers operate large-scale production facilities that rely on specialized equipment. Besides their own manufacturing sites, these companies also influence other players involved in vaccine production. Contract Development and Manufacturing Organizations (CDMOs), which handle outsourced manufacturing and are expected to grow at a CAGR of 18.88%, are another major consumer of such equipment.

Some globally prominent pharma giants in the influenza vaccine equipment market are leading influenza vaccine production - Sanofi (France), GlaxoSmithKline (UK), CSL Limited/Seqirus (Australia), AstraZeneca (UK/Sweden) and Pfizer (US). For example, Seqirus has committed to investing $140 million to expand its Holly Springs facility to boost production capacity further. Furthermore, mRNA-based influenza vaccines that Moderna and Pfizer currently have under investigation could open up new avenues for equipment innovation in coming years.

Bioreactors at the Heart of Influenza Vaccine Production, Contribute Over 22.63% revenue

Bioreactors are the most important piece of equipment in influenza vaccine manufacturing. Their ability to precisely control the environment through aeration, agitation, feeding strategies, temperature, and pH makes them optimal for maximizing yield and optimizing costs. Bioreactors now come equipped with other upstream and downstream gear, allowing efficient workflows to reduce contamination risks. Now equipped with advanced sensor technology and data analytics, they offer real-time monitoring that ensures stringent quality standards are met.

One trend points toward accelerated adoption of niche bioreactor solutions in the influenza vaccine equipment market. Single-use bioreactors make up over 85% of new installations because they can changeover rapidly and require less cleaning validation. This system is immensely valuable in the seasonally adaptive influenza vaccine landscape. There are also perfusion systems that allow continual cell growth and harvesting for a boost in productivity – these would be used for potential pandemic responses where productivity would need to increase by 12%. Micro and mini bioreactors help accelerate optimization at the R&D stage by shortening overall development timelines. Lastly, although still emerging technology - 3D bioprinting of bioreactors could revolutionize vaccine production by offering unprecedented control over cellular environment.

Inquire Before Buying This Research Report:

Niche Market Trends to Watch

• Single-Use Dominance: Single-use bioreactors are rapidly gaining ground due to benefits like reduced cleaning validation, quicker changeovers, and lowered contamination risks. This trend is particularly relevant for influenza vaccines, where frequent strain changes may be required.
• Demand for Perfusion-Based Systems: Perfusion bioreactors, which allow for continuous cell growth and product harvesting, offer increased productivity and could become crucial for meeting surge demands like those during a pandemic.
• Micro and Mini Bioreactors: These smaller units play a valuable role in early-stage research and process optimization, shortening development timelines and streamlining vaccine development.
• The Potential for 3D Bioprinting: While still in its nascent stages for vaccine production, the use of 3D-printed bioreactors could offer unprecedented control over cellular microenvironments within the bioreactor, opening new avenues for innovation in vaccine development.

Influenza Vaccine Equipment Market: Where the Future Lies?

North America's firm hold on the influenza vaccine equipment market, with a 37% revenue share, is expected to weaken. While demand may continue thanks to high illness prevalence and strong healthcare systems, production costs will rise and all that demand will already be supplied at some point. This will likely lead to a strategic shift in the industry with manufacturers partnering with technology transfer out of these markets.

Asia Pacific seems like it will become the primary growth engine in this industry. Not only do they have massive populations and increasing disposable income leading to more spending on vaccines, there's also been an increased push for self-sufficiency in vaccine manufacturing which requires more equipment sales.

Europe on the other hand may decrease investment in specialized equipment due to an aging population that may require tailored influenza vaccines.

Latin America is a tricky situation as of now. The region has huge economic disparities and so their economies fluctuate causing inconsistent markets. Government initiatives and international collaborations are going to be very important for them in creating infrastructure necessary for manufacturing vaccines and consequently increase demand on equipment.

Astute Analytica expects a lot of moving parts within this sector over the next couple years. Our analysts plan to track shifting regions, technological advancements, and changing demographics meticulously to deliver helpful insights.

Global Influenza Vaccine Equipment Market Key Players

• ALFA LAVAL
• BIOTECHNO Ltd
• Cytiva
• EMCOR Group Inc.
• Eppendorf Himac Technologies Co.
• Esco VacciXcell
• Hitachi Koki (Koki Holdings Co., Ltd.)
• ITT Engineered Valves
• MGA Technologies
• Microfluidics International Corporation
• Shikoku Instrumentation CO.,LTD.
• Other Prominent Players

Key Segmentation:

By Type

• Bioreactors
• Filtration 000' Units
• Egg Inspection Devices
• Specialized Ultracentrifuges
• Filling Machine
• Separators
• Storage And Transfer Reactors
• Freeze-Dryers
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• Medical & Research Institutes
• CDMOs

By Region

• North America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)
• South America

Explore Research Methodology @

About Astute Analytica

Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.

Contact us:
Vipin Singh
BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Email: ...
Website:

CONTACT: Vipin SinghBSI Business Park, H-15,Sector-63, Noida- 201301- IndiaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)Email: ...Website:

MENAFN04042024004107003653ID1108059620